The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The market size for vesicular monoamine transporter 2 (vmat2) inhibitors has seen rapid expansion in recent years. It is expected to increase from $1.25 billion in 2025 to $1.37 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.2%. The historical growth of this market is attributable to the approval of tetrabenazine, an uptick in antipsychotic usage, more frequent diagnosis of movement disorders, the availability of hospital-based neurology care, and a limited array of alternative therapies.

The market size for vesicular monoamine transporter 2 (vmat2) inhibitors is anticipated to demonstrate robust expansion over the next few years, projected to reach $2.01 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.9%. This expansion during the forecast period can be attributed to factors such as the rising incidence of tardive dyskinesia, the increasing utilization of deutetrabenazine, enhanced public awareness of neurological disorders, the proliferation of specialized neurology clinics, and a growing preference for oral drug formulations. Major developments expected within this period include an increase in targeted neurotransmitter modulation, intensified treatment efforts for tardive dyskinesia, the expansion of oral neurological therapeutic options, a heightened focus on managing movement disorders, and a greater adoption of long-term neurological medications.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21317&type=smp

What Drivers Are Influencing The Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market?

The rising occurrence of Parkinson’s disease is anticipated to drive the expansion of the vesicular monoamine transporter 2 (VMAT2) inhibitor market in the future. This condition is defined as a progressive neurological ailment that impairs movement, stemming from the degradation of dopamine-generating brain cells. Its escalating prevalence is largely attributed to demographic shifts towards an older population, improved diagnostic methods, environmental elements like toxins, genetic predispositions, and enhanced understanding of the illness. Vesicular monoamine transporter 2 (VMAT2) inhibitors assist in managing Parkinson’s manifestations by regulating dopamine secretion and alleviating tremors and involuntary movements. As an illustration, in October 2025, Parkinson’s UK, a charitable organization focused on research and support in the UK, projected that by 2030, the number of Parkinson’s cases in the UK would hit 173,000. Furthermore, approximately 28,000 individuals are anticipated to receive a diagnosis in 2025, translating to a new diagnosis every 20 minutes due to an expanding and aging populace. Consequently, the growing incidence of Parkinson’s disease is fueling the expansion within the vesicular monoamine transporter 2 (VMAT2) inhibitor market.

What Major Segment Divisions Exist Within The Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market?

The vesicular monoamine transporter 2 (vmat2) inhibitor market covered in this report is segmented –

1) By Drugs: Tetrabenazine, Deutetrabenazine, Valbenazine, Other Drugs

2) By Route Of Administration: Oral, Other Administrations

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By Application: Huntington’s Disease, Tardive Dyskinesia, Other Applications

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Tetrabenazine: Huntington’s Disease Treatment, Tardive Dyskinesia Management, Tourette Syndrome Treatment

2) By Deutetrabenazine: Huntington’s Disease Chorea, Tardive Dyskinesia Treatment, Off-Label Movement Disorders

3) By Valbenazine: Tardive Dyskinesia Treatment, Tourette Syndrome Research, Other Hyperkinetic Movement Disorders

4) By Other Drugs: Investigational VMAT2 Inhibitors, Emerging Therapies For Movement Disorders, Off-Label Use In Neurological Conditions

How Are Trends Shaping The Direction Of The Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market?

Companies operating in the vesicular monoamine transporter 2 (VMAT2) inhibitors market are increasingly focusing on creating innovative formulations like capsules to improve patient adherence, enhance drug stability, and optimize therapeutic effectiveness. Capsules, which are solid dosage forms enclosed within a gelatin or HPMC shell, aid VMAT2 inhibitors by boosting drug stability, ensuring precise dosing, and improving patient convenience. For example, in July 2024, Neurocrine Biosciences Inc., a US-based biopharmaceutical company, introduced Ingrezza Sprinkle (valbenazine) capsules. This new formulation of the VMAT2 inhibitor Ingrezza was developed to simplify administration for adults living with tardive dyskinesia and chorea associated with Huntington’s disease who experience dysphagia or difficulty swallowing. Ingrezza Sprinkle delivers the same effective dosing options as Ingrezza and can be administered by sprinkling its contents onto soft food or by swallowing the capsule whole.

Which Companies Are Leading Innovation In The Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market?

Major companies operating in the vesicular monoamine transporter 2 (vmat2) inhibitor market are Neurocrine Biosciences Inc., H. Lundbeck A/S, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Bausch Health Companies Inc., Luye Pharma Group Ltd., Mitsubishi Tanabe Pharma Corporation, Sumitomo Dainippon Pharma, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Lupin Limited, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Eli Lilly and Company, Merck KGaA, Johnson & Johnson, Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Biogen Inc

Read the full vesicular monoamine transporter 2 (vmat2) inhibitor market report here:

https://www.thebusinessresearchcompany.com/report/vesicular-monoamine-transporter-2-vmat2-inhibitor-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market?

North America was the largest region in the vesicular monoamine transporter 2 (VMAT2) inhibitor market in 2025. The regions covered in the vesicular monoamine transporter 2 (vmat2) inhibitor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21317&type=smp

Browse Through More Reports Similar to the Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market 2026, By The Business Research Company

Peripheral Vasodilator Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/peripheral-vasodilator-drugs-global-market-report

Anti Parkinson Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report

Anticholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anticholinergic-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model